Skip to main content
Image
Portrait of Anders Ståhlberg
Breadcrumb

Anders Ståhlberg new academic partner in the European Liquid Biopsy Society

Anders Ståhlberg, WCMTM PI, and Translational Genomics Platform, is now an academic partner of the European Liquid Biopsy Society (ELBS). An initiative by the University Hospital Hamburg-Eppendorf (UKE) to jointly promote research around liquid biopsy and its use in clinical practice.

About European Liquid Biopsy Society

With the start of 2020, the European Liquid Biopsy Society (ELBS) was established by the initiative of Prof. Klaus Pantel, physician and tumor biologist at the University hospital Hamburg-Eppendorf (UKE). Academic partner institutions and partners from industry (SME as well as large diagnostic and pharma companies) want to jointly promote research around liquid biopsy and its use in clinical practice. ELBS is open to attract new partners and will be a hub for liquid biopsy research in Europe with the key goal to translate liquid biopsy assays into clinical practice for the benefit of patients.

More information about ELBS

About Anders Ståhlberg and the Translational Genomics Platform

Our overall goal is to increase the survival and improve the quality of life for patients suffering from sarcomas characterized by FET (FUS, EWSR1, TAF15) fusion oncogenes (FET sarcomas), including more than 20 pediatric and adult cancer entities.

To accomplish this we are identifying and targeting FET fusion oncogene-specific features by applying genomics, transcriptomics and proteomics approaches that are associated with tumor development and therapy resistance. We have a particular interest in chromatin remodeling and signaling pathways like JAK-STAT and their molecular interactions with FET fusion oncoproteins. The cell transformation mechanism of FET fusion oncogenes are studied using innovative 3D and in vivo experimental models.

More information about Anders Ståhlberg and the Translational Genomics Platform